MET and lung carcinoma: The multi-kinase inhibitor cabozantinib, which has demonstrated activity against ALX, KIT, MET, RET, ROS1, VEGFR2 and TIE2 [88], and is already approved for the treatment of medullary thyroid and renal cell carcinoma [89,90,91], has been administered by Drilon et al. in a phase II study enrolling lung cancer patients [75].